|
|
101 Enterprise, Suite 300 Aliso Viejo, CA 92656 USA phone:(949) 389-6700 fax:(718) 921-8334
|
|
| Symbol |
AVNR |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
63 |
|
|
| www.avanir.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Treatments for CNS disorders and inflammatory diseases. |
 |
| Management |
| Stephen G. Austin, Cpa, Independent Director; Keith A. Katkin, Inside Director; Charles A. Mathews, Independent Director; David J. Mazzo, Ph.D., Independent Director; Dennis G. Podlesak, Independent Director |
| |
|
|
|
|
|
|
|
| Keywords |
| inflammatory, cold sores, herpes, central nervous disorders, cardiovascularm infectious |
|
|
|
| Description |
|
AVANIR PHARMACEUTICALS is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR'S products and product candidates address therapeutic markets that include central nervous system disorders, cardiovascular disorders, inflammation, and infectious disease. |
 |
| Products / Services |
The company's first commercialized product, abreva?, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Avanir also markets FazaClo?, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments.
|
 |
 |
| Strategy |
The company's first commercialized product, abreva?, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.
|
 |
| Status |
| Zenvia(tm), Avanir's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), is the subject of an approvable letter from the FDA and future development plans for this product candidate are under consideration. |
 |
|
|
|
|
|
|